390 Million Annual Infections Drive Search for New Dengue Targets

Most antiviral research starts with the same instinct: find something unique to the virus and destroy it. It’s a reasonable instinct. But dengue has spent millions of years evolving inside human cells, and it has learned to hide inside processes so fundamental to normal cell function that targeting the virus directly, without touching the machinery it borrows, may be asking the wrong question. Understanding how dengue virus evades the immune system means looking not just at the virus, but at what it does to you.

With an estimated 390 million infections every year, dengue is not a rare or regional problem. It’s one of the most common mosquito-borne viral diseases on the planet, and existing treatment options remain limited to managing symptoms. A review published in Virology Journal in 2025 maps the full range of metabolic processes dengue exploits inside the host cell, and in doing so, points toward a different class of targets entirely.

The conventional framing has been that dengue suppresses immunity as a kind of side effect of infection. Research has documented pieces of this: altered glucose use here, disrupted fat metabolism there, a blunted interferon response somewhere else. What has been missing is a unified picture of how these changes connect, reinforce each other, and together allow the virus to replicate thousands of times before the immune system can mount a coherent reply. Without that picture, therapeutic targets have remained scattered.

Imagine a small, unauthorized contractor sneaking into a factory and quietly reprogramming every machine to manufacture their own product instead of the factory’s usual goods. The contractor does not announce itself. It simply starts rerouting workflows, one department at a time, until the entire facility is producing something the factory never agreed to make. The alarm system gets cut from the inside, so no help arrives.

In this analogy, the factory is your cell, and the contractor is dengue virus. The sugar-burning equipment the contractor reprograms is glycolysis, the cell’s primary energy-production pathway, which dengue diverts to generate the fuel and raw materials it needs to replicate. The fat storage system the contractor raids corresponds to lipid droplets, which dengue uses as a source of membrane components to wrap each new virus particle. The alarm system that gets cut is the interferon signaling pathway, specifically the JAK/STAT cascade, which would normally broadcast a distress signal to the immune system. In cell and animal models, this coordinated reprogramming allows dengue to produce thousands of copies of itself before the immune response can organize a meaningful reply.

The review integrates research across glucose, lipid, amino acid, and mitochondrial metabolism to show that these are not parallel disruptions. They are a coordinated system. Dengue activates the PI3K/Akt/mTOR pathway to shift the cell toward the kind of metabolic state that favors rapid biosynthesis over normal homeostasis. It upregulates fatty acid synthase (FASN) to increase lipid production, and it exploits GAPDH, an enzyme in the glycolytic pathway, in ways that extend beyond energy generation into gene expression regulation. Each of these nodes represents a point where the virus depends on the host cell’s own machinery.

That dependency is also a vulnerability. Because the virus cannot replicate without these host pathways, blocking them becomes a potential strategy. The review identifies several investigational approaches, including glycolysis inhibitors, lipid metabolism modulators, and metformin, a widely used diabetes drug that affects cellular energy sensing and is being studied in infectious disease contexts. These are not established treatments for dengue. They are research directions, each requiring further investigation before anyone can speak to clinical efficacy or safety in this context.

TAM co-author Francesco Marincola contributed to this review. Dr. Marincola is Chief Scientific Officer of TAM Global, and his involvement reflects TAM’s broader focus on immunology and the intersection of host biology with disease response.

What this review makes possible is a more organized target selection process for dengue drug development. By mapping the specific nodes where viral replication depends on host metabolism, researchers now have a clearer framework for deciding which inhibitors are worth pursuing in preclinical models, and which combinations might address both replication and immune suppression at once. The clinical path remains long. But the conceptual architecture for host-directed dengue therapy is more complete than it was.

If you are tracking antiviral drug development, following research in dengue-endemic regions, or exploring how metabolic biology intersects with infectious disease, this paper is worth reading directly. The direction it points toward, treating the cell’s reprogrammed state rather than the virus in isolation, may reshape how researchers approach not just dengue, but other viruses that use the same playbook.